Abstract

Glioblastoma multiforme (GBM) is the deadliest form of brain tumors. To date, the GBM therapeutical approach consists of surgery, radiation-therapy and chemotherapy combined with molecules improving cancer responsiveness to treatments. In this review, we will present a brief overview of the GBM classification and pathogenesis, as well as the therapeutic approach currently used. Then, we will focus on the modulatory role exerted by pituitary adenylate cyclase-activating peptide, known as PACAP, on GBM malignancy. Specifically, we will describe PACAP ability to interfere with GBM cell proliferation, as well as the tumoral microenvironment. Considering its anti-oncogenic role in GBM, synthesis of PACAP agonist molecules may open new perspectives for combined therapy to existing gold standard treatment.

Highlights

  • IntroductionGliomas represent the most frequent malignant tumor affecting the central nervous system (CNS), including all glial cell-derived cancers

  • MTA-PTE Pituitary adenylate cyclase-activating polypeptide (PACAP) Research Group, Department of Anatomy, University of Pécs Medical School, These authors contributed

  • Pituitary adenylate cyclase-activating polypeptide (PACAP) is a peptide that belongs to the secretin/glucagon/growth hormone-releasing hormone/vasoactive intestinal peptide (VIP) family members, widely expressed in the central nervous system (CNS) and in peripheral organs where it exerts different roles in a tissue-specific manner [79,80,81,82,83,84]

Read more

Summary

Introduction

Gliomas represent the most frequent malignant tumor affecting the central nervous system (CNS), including all glial cell-derived cancers. Based on World Health Organization classification, four types of gliomas can be classified: astrocytoma of grade I and grade I, representing astrocytic tumor, the grade III astrocytoma, consisting in anaplastic tumor, and grade IV astrocytoma or glioblastoma multiforme (GBM) [1] The latter represents the deadliest brain cancer, with high cell heterogeneity and poor prognosis since it is characterized by therapeutic resistance and relapse after surgery. To counteract this issue, many studies have focused on identification of a new therapeutic approach consisting in co-administration of new molecules to the existing gold-standard treatment.

Glioblastoma Multiforme
PACAP and Its Related Receptors in Cancer
PACAP Involvement in GBM Malignancy
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call